About Sharklet Technologies
Sharklet Technologies is a biotechnology company that develops surface technologies that are designed to inhibit microorganism growth to make the world a healthier, environmentally safer and better place. Inspired by the microbial-resistant properties of sharkskin, Sharklet, the company's core technology, is the world's first micro-texture developed to control bacteria including Staph a., MRSA, VRE, E. coli and a host of others. Sharklet is suited for commercial, healthcare, and high-touch environments where bacterial inhibition is desired.
Sharklet Technologies Patents
Sharklet Technologies has filed 21 patents.
Metal forming, Glass art, Lathes, Tubing (material), Casting (manufacturing)
Metal forming, Glass art, Lathes, Tubing (material), Casting (manufacturing)
Latest Sharklet Technologies News
Nov 11, 2021
An increase in the prevalence of acute renal failure and congestive heart failure along with the progression of the Continuous Renal Replacement Therapy from adaptive renal devices to the multipurpose treatment machines are driving the growth of the Continuous Renal Replacement Therapy Devices Market News provided by Share this article Share this article LAS VEGAS, Nov. 11, 2021 /PRNewswire/ -- DelveInsight's Continuous Renal Replacement Therapy Devices Market Insights and Forecast report provides the current and forecast Continuous Renal Replacement Therapy Devices market, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Continuous Renal Replacement Therapy Devices market. According to the latest analysis by DelveInsight, North America is expected to dominate the overall Continuous Renal Replacement Therapy Devices market during the forecast period. Major pharma giants working proactively in the Continuous Renal Replacement Therapy Devices market include Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, NIKKISO CO., LTD., B. Braun Melsungen AG, Asahi Kasei Corporation, Informed SA, Medtronic, and others. As per an estimate by DelveInsight, Global Continuous Renal Replacement Therapy Devices Market was valued at USD 1.17 billion in 2020, growing at a tremendous CAGR of 7.38% during the forecast period from 2021 to 2026, and is anticipated to reach USD 1.78 billion by 2026. In August 2020, Baxter had obtained US FDA Emergency Use Authorization for Regiocit Replacement Solution used in Continuous Renal Replacement Therapy. Under the EUA, Regiocit is authorized to be used in the case of adults only that are being treated utilizing Continuous Renal Replacement Therapy. In April 2020, Fresenius Medical Care had received US FDA Emergency Use Authorization for multifiltrate PRO System and multiBic/multiPlus Solutions for providing Continuous Renal Replacement Therapy so that patients can be treated in an acute care environment during the COVID-19 pandemic. On April 29, 2020, the FDA had granted the marketing of new Continuous Renal Replacement Therapy Devices being used in pediatric patients with certain kidney conditions. Interested in knowing how the Continuous Renal Replacement Therapy Devices Market will be growing by 2026? Click to get a snapshot of Continuous Renal Replacement Therapy Devices Market Scenario Continuous Renal Replacement Therapy is the most common treatment option for patients that are critically ill along with patients suffering from acute kidney injury (ACI), specifically those that are hemodynamically unstable. During this therapy, the patient's blood tends to pass via a special filter that removes fluid and uremic toxins, thereby returning clean blood to the body. The slow and continuous nature of the process, typically performed for a 24-hour period, thus allowing the patients that are suffering from unstable blood pressure and heart rates, also termed as hemodynamically unstable, so that the process can be well tolerated. It is a different type of dialysis than the regular one and requires both special skills and expertise. To pick on the latest highlights related to Continuous Renal Replacement Therapy Devices get the snapshot of the key highlights entailed in the Continuous Renal Replacement Therapy Devices Market report. At present, the manufacturers are developing precise devices that are safe and give a reliable performance during Continuous Renal Replacement Therapy procedures. For ease of performance, these devices are equipped with the latest, user-friendly interface. Continuous Renal Replacement Therapy is the most common treatment option for patients that are critically ill along with patients suffering from acute kidney injury (ACI), specifically those that are hemodynamically unstable. During this therapy, the patient's blood tends to pass via a special filter that removes fluid and uremic toxins, thereby returning clean blood to the body. That is the sole reason why Continuous Venovenous Hemofiltration (CVVH) holds the major market share In the Continuous Renal Replacement Therapy market modality segment. Recently, in 2021, Baxter announced the launch of its latest version of the next-generation CRRT platform, PrisMax 2. This system features new solutions within the company's TrueVue digital health portfolio and is designed to help simplify the delivery of Continuous Renal Replacement Therapy (CRRT). Various launches in the Continuous Renal Replacement Therapy Devices arena are held accountable for the growth of the market, for instance on December 08, 2020, Medtronic plc. had launched the Carpediem™ Cardio-Renal Pediatric Dialysis Emergency Machine, the first and only pediatric and neonatal acute dialysis machine in the United States. Curious to understand why North America is dominating the global market? Click to get a snapshot of Continuous Renal Replacement Therapy Devices Market Analysis. Owing to the various benefits that are offered by the Continuous Renal Replacement Therapy Devices such as the continuous control of the fluid status, hemodynamic stability, control of acid–base status and the ability to provide protein-rich nutrition while achieving uremic control will lead to an increase in the demand of these Continuous Renal Replacement Therapy Devices. Additionally, other advantages offered by the Continuous Renal Replacement Therapy Device such as the control of electrolyte balance including phosphate and calcium balance, prevention of swings in intracerebral water, and high level of biocompatibility along with their versatile use in patients suffering from cerebral edema, tends to increase the demand for such devices among the patients affected from renal failure, thus driving the Continuous Renal Replacement Therapy Devices Market. Other factors like increasing demand for several Continuous Renal Replacement Therapy procedures, recent launches and approvals of the Continuous Renal Replacement Therapy Devices and the advanced innovation witnessed in the manufacturing of machines also sum up the increment anticipated to observe in the Continuous Renal Replacement Therapy Devices Market. The market for Continuous Renal Replacement Therapy Devices observed a period of slow growth due to the outbreak of COVID-19. Owing to the shutting down of manufacturing units, trade restrictions and fewer hospital visits during the pandemic, the Continuous Renal Replacement Therapy Devices Market growth had witnessed stagnancy during this period. To discuss more regarding the short and long-term impact of COVID-10 get a snapshot of the report Continuous Renal Replacement Therapy Devices market @ Continuous Renal Replacement Therapy Devices Market Landscape Study Period: 2018-2026 Key Companies: Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, NIKKISO CO., LTD., B. Braun Melsungen AG, Asahi Kasei Corporation, Informed SA, Medtronic, and others. Continuous Renal Replacement Therapy Devices Market Segmentation By Modality Understand the Competition, Risk Assessment and effective Research and Development approach to take value-based decisions. Related Reports 'Pulse Oximeters Market' was valued at USD 1.9 billion in 2020, growing at a CAGR of 10.13% during the forecast period from 2021 to 2026, to reach USD 3.3 billion by 2026. The demand for Pulse Oximeters is primarily attributed to the sudden outbreak of the COVID-19 pandemic, rising prevalence of various respiratory disorders, technological advancement, and the entrance of key companies such as Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation, Meditech Equipment Co, and many others. DelveInsight's 'Renal Denervation Devices - Market Insights, Competitive Landscape and Market Forecast–2026' report delivers an in-depth understanding of Renal Denervation Devices and the historical and forecasted Renal Denervation Devices market trends, market drivers, market barriers and key companies involved such as Medtronic PLC, Otsuka Holdings Co, Ablative Solutions Inc, Mercator MedSystems, Terumo Corporation, Symple Surgical, Boston Scientific Corporation, SoniVie, and many others. DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast—2030' report delivers an in-depth understanding of Chronic Insomnia, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Eisai Inc, Merck & Co, Idorsia Pharmaceuticals, Janssen Research & Development, Minerva Neurosciences, Sequential Medicine Ltd, and many others. DelveInsight's, "Urinary Catheters–Pipeline Insight and Competitive Landscape 2020," report provides comprehensive insights about 20+ pipeline devices in the Urinary Catheters pipeline and 20+ companies such as Brighton Development LLC, Control Flo Medical LLC, Flat Medical Inc, FocusStart LLC, InterVaal Pte Ltd, Leading Age Supplies LLC, N8 Medical Inc, Olympus Medical Systems Corp, Provenmed, Pyriscence LLC, Riocath Global AS, Sharklet Technologies Inc, and several others.
Sharklet Technologies Frequently Asked Questions (FAQ)
Where is Sharklet Technologies's headquarters?
Sharklet Technologies's headquarters is located at 12635 E. Montview Boulevard, Aurora.
What is Sharklet Technologies's latest funding round?
Sharklet Technologies's latest funding round is Acquired.
How much did Sharklet Technologies raise?
Sharklet Technologies raised a total of $3.36M.
Who are the investors of Sharklet Technologies?
Investors of Sharklet Technologies include Peaceful Union, Altria Ventures, National Institutes of Health and Sid Martin Biotechnology Incubator.
Who are Sharklet Technologies's competitors?
Competitors of Sharklet Technologies include Sagimet Biosciences, Elusys Therapeutics, Intralytix, Checkpoint Surgical, GangaGen and 13 more.
Compare Sharklet Technologies to Competitors
GangaGen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences.
Pulmotect develops host-directed or pathogen-agnostic products to reduce morbidity and mortality in patients at risk of severe respiratory diseases. It offers immunomodulatory and pathogen-agnostic approaches to prevent and treat respiratory complications. The company was founded in 2007 and is based in Houston, Texas.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Avigenics is a company that received a SBIR Phase I grant for a project entitled: Production of Transgenic Poultry Resistant to Avian Influenza Infection by RNAi. Their project generates transgenic poultry resistant to avian influenza (AI) virus through RNA interference (RNAi) technology. Poultry are vulnerable to AI infections that can rapidly reach mortality rates approaching 100%. Current vaccines provide only limited protection, with prophylaxis based on surveillance and diagnosis, followed by rapid depopulation and disposal of infected or exposed birds and quarantine and disinfection of farms and equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), (ii) establish stable cell lines hosting siRNAs vectors and (iii) test the efficacy of siRNAs against AI viruses. Three siRNAs shown to effectively inhibit AI viruses will be used to generate cell lines, which will be challenged with 5 different AI viruses to determine whether these vectors, when integrated into the avian genome, can effectively inhibit AI viruses. The broader impact of this research will be to improve the biosecurity of biopharmaceutical production in poultry as the avian influenza virus spreads and well as potentially protecting the food supply from natural as well as bioterrorist threats should these transgenic chickens gain wide approval in the marketplace.
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
ParaTechs applies advances in insect molecular biology to identify genes and proteins from insect parasites and pathogens that can be used for insect control and natural product development. ParaTech also markets products that enable discovery and development in biotechnology.